Where do you see the field of long-acting delivery evolving? The field of long-acting drug delivery is set for substantial growth and innovation, poised to transform treatment options for various ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase I study ...
In this third of four exclusive episodes, MedPage Today brought together three expert leaders in the field -- moderator Leslie Citrome, MD, MPH, of New York Medical College in Valhalla, is joined by ...
Scientists have developed an injectable drug that blocks HIV from entering cells. They say the new drug potentially offers long-lasting protection from the infection with fewer side effects. The drug, ...
Prof. Stewart Cole, Chairman of the Board of iM4TB, said: “Long-acting injectable antiretroviral formulations have simplified, and radically improved HIV-AIDS treatment and we are confident that this ...
Clinics have been coming up with new ways to add injections to their offerings ever since a new long-acting formulation of cabotegravir has been available to treat people with HIV. At the ...
Hosted on MSN
Insulin’s journey from miracle to modern must-have
From its groundbreaking discovery in 1921 to today’s high-tech delivery systems, insulin has saved millions of lives and continues to be a cornerstone of diabetes care. Modern options range from rapid ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median ...
Hosted on MSN
How long-acting injectable treatment could transform care for postpartum women with HIV
For breastfeeding women who have HIV, consistently taking antiretroviral therapy (ART) is essential for their own health and the health of their infants. New long-acting (LA) injectable ART options, ...
Data show for the first time a new ultra long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval Pharmacokinetic, tolerability and safety data supports moving CAB-ULA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results